Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $6.71, but opened at $7.46. Telix Pharmaceuticals shares last traded at $7.8170, with a volume of 117,335 shares traded.

Wall Street Analysts Forecast Growth

TLX has been the subject of a number of analyst reports. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Price Performance

The business has a fifty day simple moving average of $7.54 and a two-hundred day simple moving average of $9.31.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers increased its holdings in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Telix Pharmaceuticals in the 4th quarter worth $89,000. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth $213,000. OLD Mission Capital LLC bought a new position in Telix Pharmaceuticals in the 4th quarter worth $111,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Telix Pharmaceuticals in the 2nd quarter worth $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.